How do sulfonylureas work?

They bind and close the ATP-sensitive potassium channel directly, bypassing the glucose metabolism step that normally closes it.

Why does that cause hypoglycaemia?

Release becomes unconditional. If glucose falls, nothing signals the cell to stop secreting insulin.

Does adding a GLP-1 agonist reduce that risk?

No. Glucose-dependence protects the incretin's own action; it does not restrain a second agent acting independently.

GLP-1 & Incretin Science

Forcing the Channel Shut Regardless of Glucose

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Sulfonylureas close the ATP-sensitive potassium channel directly rather than through glucose metabolism. Because they bypass the sensing step, they drive insulin release whether or not glucose is elevated — which is the mechanistic source of their hypoglycaemia risk.

Key facts

Target: ATP-sensitive potassium channel
Action: Closes it pharmacologically
Bypasses: The glucose-sensing step
Consequence: Insulin release regardless of glucose
Contrast with GLP-1: Amplifier versus trigger
Example agents: Glimepiride, glibenclamide

The step they act on

In normal beta cell physiology, glucose metabolism raises ATP and rising ATP closes the potassium channel. Sulfonylureas bind that channel and close it themselves. Everything downstream — depolarisation, calcium entry, granule release — then proceeds exactly as it would have, but without glucose having been involved.

Why bypassing the sensor is the whole problem

The glucose-sensing step is what makes insulin release appropriate. Remove it and release becomes unconditional: the cell secretes because a drug is present, not because glucose is high. If glucose then falls, nothing tells the cell to stop, and that is how the level is driven below normal.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

The contrast stated precisely

GLP-1 is a gain control on a glucose-initiated signal — applied to zero it produces zero. A sulfonylurea is an independent trigger — it produces output regardless of input. Both increase insulin secretion, and only one of them can do so when it should not.

Why this is not an argument against sulfonylureas

They lower glucose effectively, they are inexpensive, and they have decades of use behind them. The hypoglycaemia risk is a known and managed property rather than a hidden flaw. The point is that it is intrinsic to the mechanism and therefore cannot be engineered out of the class.

What happens when the two are combined

The regimen inherits the sulfonylurea's behaviour. An incretin's glucose-dependence protects what the incretin does; it does nothing about a second agent forcing release independently. This is visible directly in trial data where participants are stratified by sulfonylurea use.

Why the distinction matters for reading safety figures

A hypoglycaemia rate quoted for an incretin without stating background therapy is uninterpretable. The same compound can show 1 to 3% or 6 to 9% depending entirely on what else the participants were taking, and the difference is not a property of the incretin.

Quick reference

	GLP-1 agonist	Sulfonylurea
Acts as	Amplifier	Independent trigger
Requires glucose	Yes	No
Channel closure	Via glucose metabolism	Pharmacological, direct
Hypoglycaemia alone	Uncommon	Established risk

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How do sulfonylureas work?: They bind and close the ATP-sensitive potassium channel directly, bypassing the glucose metabolism step that normally closes it.
Why does that cause hypoglycaemia?: Release becomes unconditional. If glucose falls, nothing signals the cell to stop secreting insulin.
Does adding a GLP-1 agonist reduce that risk?: No. Glucose-dependence protects the incretin's own action; it does not restrain a second agent acting independently.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum